<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03098901</url>
  </required_header>
  <id_info>
    <org_study_id>KMC-0018-17</org_study_id>
    <nct_id>NCT03098901</nct_id>
  </id_info>
  <brief_title>Radioisotope Scintigraphy to Establish Incidence of Cardiac Amyloidosis Among Patients With Otherwise Unexplained Cardiac Disease</brief_title>
  <official_title>Tc99m-PYP Scintigraphy in Order to Establish Incidence of Cardiac Transthyretin Amyloidosis Among Patients With Otherwise Unexplained Cardiomyopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaplan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaplan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac amyloidosis is a multi-organ syndrome, which usually presents as restrictive
      cardiomyopathy (RCM). Transthyretin (TTR) amyloidosis (or ATTR) is a subtype of amyloidosis
      which frequently involves heart. Cardiac ATTR, though infrequently diagnosed during lifetime,
      may represent a prevalent cause of RCM, especially in elderly. Several medications that can
      limit progression of the disease are currently under investigation. Presently the golden
      standard for diagnosis of ATTR is endomyocardial biopsy (EMB) which may entail severe adverse
      complications causing under-diagnosis of ATTR.

      Several papers support the evidence that Tc99m-labeled tracers can be used to detect
      myocardial deposits of TTR amyloid. It was suggested that Tc99m scintigraphy might be a
      highly sensitive diagnostic tool for cardiac ATTR. In this study the patients with otherwise
      unexplained cardiomyopathy or heart block will undergo Tc99m scan, which will establish the
      incidence of this largely underdiagnosed condition in the population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Amyloidosis is a multi-organ syndrome, which usually presents as a restrictive cardiomyopathy
      (RCM). Transthyretin (TTR) amyloidosis is a subtype of amyloidosis, further subdivided into
      familial type and senile type. Its pathophysiology consists primarily of abnormal
      precipitation of transthyretin - a protein that normally acts as transporter for thyroid
      hormone and retinoids - in tissues. TTR amyloidosis frequently involves heart, bringing about
      the same clinical and pathophysiological picture of RCM. Another presentation of TTR
      Amyloidosis can be atrio-ventricular block or bundle-branch block [1].

      There is evidence that the cardiac TTR amyloidosis, though infrequently diagnosed during the
      lifetime, may represent a widespread cause of restrictive cardiomyopathy especially in
      elderly. An autopsy study in octogenarians having suffered of heart failure with preserved
      left ventricular ejection fraction (HFpEF) suggested that up to 25% of them had TTR amyloid
      deposit in myocardium, though a negligible minority of them had been diagnosed with TTR
      amyloidosis during their lifetime [2-3]. HFpEF is a very widespread diagnosis, which
      represents a considerable burden of morbidity, and usually harbours populations of patients
      poorly responding to treatment. Most of patients with the diagnosis of HFpEF have little or
      no explanation concerning the aetiology of their disease, especially if they do not respond
      to conventional treatment. Most of them can benefit only from symptomatic treatment which
      does not alter the course of the disease. Thus a more widespread diagnosis of TTR amyloidosis
      could have been very promising as to a better management of this hard-to-treat patient
      population.

      Several medications that can limit progression of TTR amyloidosis are currently under
      investigation. Until now, the golden standard for diagnosis of the disease was endomyocardial
      biopsy (EMB) which may entail several adverse complications and thus limit widespread
      diagnosis. Since amyloidosis is a multi-organ disease, extra-cardiac biopsy was proposed as a
      surrogate tissue diagnosis, though in TTR amyloidosis its sensitivity is below 50% [4].

      Recently several papers support the evidence that Tc99m-labeled pyrophosphate (PYP) and
      bisphosphonates when injected intravenously localize to myocardial deposits of TTR amyloid.
      It was thus suggested that Tc99m scintigraphy might be a highly sensitive and specific
      diagnostic tool for cardiac TTR amyloidosis [5-9]. It was shown that almost the only source
      of false positive Tc99m scintigraphy is primary amyloidosis, which is a different entity,
      with worse prognosis, different treatment, although frequently involves heart as well [10].
      Primary amyloidosis can be diagnosed by means of demonstration of monoclonal immunoglobulin
      peak in serum and immunoglobulin light chains in serum and urine [11]. Therefore, the
      specificity of Tc99m scan for TTR amyloidosis can be brought to an extraordinary level, with
      virtually negligible false positive rate, if primary amyloidosis is excluded prior to
      referral to Tc99m scan. The other entity where false positive uptake of Tc99m in myocardium
      can be observed is acute myocardial infarction. Currently the Tc99m-PYP scan is utilised as
      bone scan according to guidelines in order to diagnose wide spectrum of diseases such as
      stress fractures or metastatic bone disease.

      At present the mentioned hypothesis that TTR amyloidosis might be a widespread cause of HFpEF
      has not been established in a clinical trial due to the fact that until now the most accurate
      diagnosis of TTR amyloidosis required an invasive procedure with possible adverse outcomes
      while the extra-cardiac biopsy had low diagnostic yield. Advent of a novel, possibly as
      accurate, yet non-invasive diagnostic tool opens new opportunities to set such study.

      The incidence of both familial type and senile type TTR amyloidosis among patients with
      diagnosis of otherwise unexplained heart failure or heart block will be evaluated in this
      study by means of Tc99m scan using SPECT technology as described above. The hypothesis is
      that if the incidence of TTR amyloidosis within the population of patients suffering of HFpEF
      is as high as it was demonstrated by the autopsy studies, then we will be able to establish
      the diagnosis in a larger cohort of patients. This will make new developments in the research
      of the disease, such as treatment and outcome driven trials, possible.

      Establishing the diagnosis of TTR amyloidosis in patients with HFpEF will improve our
      decision-making ability regarding the patients' treatment, for example preventing unnecessary
      invasive measures in patients with comorbidities demanding such measures, the alternative
      diagnoses being unrevealed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 15, 2017</start_date>
  <completion_date type="Anticipated">April 15, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients that suffer of one of the following conditions will be included in the study
Patients suffering of HFpEF not explained by either hypertension or any other clinical condition.
Patients with systolic dysfunction and non-significant coronary artery disease.
Patients with diabetic cardiomyopathy
Patients with otherwise unexplained left ventricular hypertrophy (LVH).
Patients under age of 65 with idiopathic ventricular fibrillation (VF) or multiple ventricular premature beats (VPB) or ventricular tachycardia (VT) with a structurally normal heart.
Patients under age of 65, with unexplained sinus node disease, sinoatrial block, complete or high-degree atrio-ventricular block or significant intraventricular conduction defect, with structurally normal heart whether having or not having received permanent implanted pacemaker.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>diagnosis or exclusion of any type of cardiac amyloidosis;</measure>
    <time_frame>immediately at the Tc99m scan performing or within a year form beginning of the recruitment</time_frame>
    <description>diagnosis of cardiac TTR amyloidosis, or any other type of cardiac amyloidosis, or diagnosis of another condition other than amyloidosis explaining the patient's clinical cardiological findings</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cardiac TTR Amyloidosis</condition>
  <arm_group>
    <arm_group_label>no other arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Tc99m-labeled pyrophosphate scan</intervention_name>
    <description>Intravenous injection of Tc99m-labeled pyrophosphate with consecutive whole body scan using gamma ray scanner for assessment of radioactive uptake in the heart. The results of the scan will be evaluated by a specialist in the field. The uptake will be graded using Perugini scale (0- no uptake, 1- uptake in heart less intense than in bones, 2-uptake in heart as intense as in bones, 3-uptake in heart more intense than in bones).</description>
    <arm_group_label>no other arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Heart Failure with Preserved Ejection Fraction not explained by either hypertension or
             any other clinical condition.

          2. Systolic dysfunction and non-significant coronary artery disease.

          3. Diabetic cardiomyopathy

          4. Otherwise unexplained left ventricular hypertrophy (LVH).

          5. Under age of 65 and idiopathic ventricular fibrillation (VF) or multiple ventricular
             premature beats (VPB) or ventricular tachycardia (VT) with a structurally normal
             heart.

          6. Under age of 65, and unexplained sinus node disease, sinoatrial block, complete or
             high-degree atrio-ventricular block or significant intraventricular conduction defect,
             with structurally normal heart whether having or not having received permanent
             implanted pacemaker.

        Exclusion Criteria:

          1. Primary amyloidosis cannot be excluded,

          2. Acute or recent (3 months) myocardial infarction,

          3. Acute or recent (12 months) myocarditis,

          4. Oncologic or any other co-morbidity, which can shorten the patient's survival to less
             than one year,

          5. End stage renal disease treated with dialysis,

          6. Ischemic cardiomyopathy,

          7. Non-TTR amyloidosis known or suspected,

          8. Another type of cardiomyopathy (for ex. arrhythmogenic right ventricular dysplasia),

          9. Any disease or clinical condition that can lead to cardiomyopathy (history of
             anthracyclines treatment, history of alcohol abuse, multiple myeloma, sarcoidosis,
             carcinoid, inflammatory and autoimmune diseases).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <reference>
    <citation>Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012 Sep 4;126(10):1286-300. doi: 10.1161/CIRCULATIONAHA.111.078915. Review.</citation>
    <PMID>22949539</PMID>
  </reference>
  <reference>
    <citation>Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, Myllykangas L. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232-9. doi: 10.1080/07853890701842988.</citation>
    <PMID>18382889</PMID>
  </reference>
  <reference>
    <citation>Fine NM, Arruda-Olson AM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kyle RA, Swiecicki PL, Scott CG, Grogan M. Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol. 2014 May 15;113(10):1723-7. doi: 10.1016/j.amjcard.2014.02.030. Epub 2014 Mar 2.</citation>
    <PMID>24698461</PMID>
  </reference>
  <reference>
    <citation>Maurer MS. Noninvasive Identification of ATTRwt Cardiac Amyloid: The Re-emergence of Nuclear Cardiology. Am J Med. 2015 Dec;128(12):1275-80. doi: 10.1016/j.amjmed.2015.05.039. Epub 2015 Jun 17. Review.</citation>
    <PMID>26091765</PMID>
  </reference>
  <reference>
    <citation>Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005 Sep 20;46(6):1076-84.</citation>
    <PMID>16168294</PMID>
  </reference>
  <reference>
    <citation>Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, Ferlini A, Salvi F, Gallo P, Gagliardi C, Branzi A. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):470-8. doi: 10.1007/s00259-010-1642-7. Epub 2010 Nov 11.</citation>
    <PMID>21069320</PMID>
  </reference>
  <reference>
    <citation>Bokhari S, Casta√±o A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013 Mar 1;6(2):195-201. doi: 10.1161/CIRCIMAGING.112.000132. Epub 2013 Feb 11.</citation>
    <PMID>23400849</PMID>
  </reference>
  <reference>
    <citation>Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016 Jun 14;133(24):2404-12. doi: 10.1161/CIRCULATIONAHA.116.021612. Epub 2016 Apr 22.</citation>
    <PMID>27143678</PMID>
  </reference>
  <reference>
    <citation>Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995 Jan;32(1):45-59.</citation>
    <PMID>7878478</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2017</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaplan Medical Center</investigator_affiliation>
    <investigator_full_name>Sara Shimoni</investigator_full_name>
    <investigator_title>Dr Sara Shimoni</investigator_title>
  </responsible_party>
  <keyword>TTR Amyloidosis</keyword>
  <keyword>Heart Failure with Preserved Ejection Fraction</keyword>
  <keyword>Ventricular arrhythmia</keyword>
  <keyword>Cardiac Conduction Disturbances</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

